Clinical Trial Update: Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine for advanced or recurrent squamous cell carcinoma of the skin has been terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Stanford University | Conditions: Squamous Cell Carcinoma of the Skin, Recurrent Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-10